KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Amortization of Deferred Charges: 2010-2025

Historic Amortization of Deferred Charges for Neogenomics (NEO) over the last 14 years, with Sep 2025 value amounting to $9,000.

  • Neogenomics' Amortization of Deferred Charges fell 80.85% to $9,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $126,000, marking a year-over-year decrease of 32.62%. This contributed to the annual value of $189,000 for FY2024, which is 2.16% up from last year.
  • Latest data reveals that Neogenomics reported Amortization of Deferred Charges of $9,000 as of Q3 2025, which was down 57.14% from $21,000 recorded in Q2 2025.
  • Neogenomics' Amortization of Deferred Charges' 5-year high stood at $48,000 during Q4 2024, with a 5-year trough of $9,000 in Q3 2025.
  • Over the past 3 years, Neogenomics' median Amortization of Deferred Charges value was $47,000 (recorded in 2024), while the average stood at $41,091.
  • In the last 5 years, Neogenomics' Amortization of Deferred Charges surged by 73.08% in 2021 and then tumbled by 80.85% in 2025.
  • Quarterly analysis of 5 years shows Neogenomics' Amortization of Deferred Charges stood at $45,000 in 2021, then grew by 2.22% to $46,000 in 2022, then remained steady at $46,000 in 2023, then climbed by 4.35% to $48,000 in 2024, then crashed by 80.85% to $9,000 in 2025.
  • Its Amortization of Deferred Charges stands at $9,000 for Q3 2025, versus $21,000 for Q2 2025 and $48,000 for Q1 2025.